The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Merck said on Monday it expects a commercial opportunity exceeding $5 billion from Cidara Therapeutics' experimental flu drug ...

Q3 2025 Management View CEO Ryan Spencer highlighted top line growth and market share expansion for HEPLISAV-B, the advancement of multiple clinical programs, execution of a strategic license with ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 ...

The company said, “Over the near term, Moderna (MRNA) will continue to build a large seasonal vaccine franchise targeting at-risk populations and ...

On September 18th, the Centers for Disease Control and Prevention's vaccine advisory committee voted to make a significant change to the nation's childhood vaccine schedule during its first gathering ...

A new survey conducted by Pew Research Center highlights some of the biggest issues in the ongoing controversy over vaccines—and shows that politics continues to have an outsized influence on how ...